

Morning Comments

Fiscal “Cliffhanger”

- U.S. Presidential and Congressional elections came and went almost exactly as polls anticipated. But the results leave us no more certain about the timing and nature of compromises needed to address the fiscal cliff, much less longer-term fiscal rebalancing. Weakening financial markets suggest a (fading) complacency that the election’s conclusion would clarify the policy outlook.
- While the world waits for such clarity, increasing evidence points to delays in business decision making that will take a toll on U.S. growth in late 2012. This is independent of actual new fiscal tightening set to begin in 2013 if there are no agreements.
- While many suggest a political solution will be easier to achieve after temporary aspects of the U.S. tax code have been allowed to expire, the damage done to the economy may be deepening and self reinforcing if action is delayed over another calendar quarter. We continue to expect some bridging actions to avoid severe and abrupt tightening before year end. Further delay would suggest sizeable downside risk for the U.S. economy.
- Immediate fiscal tightening would be ill timed given a net employment loss of 4 million in the past five years. At the same time, the revenue challenge presented by a tripling growth rate of the baby boom demographic is impossible to ignore. It is especially hard to see a sustainable long-term fiscal outlook given *bi-partisan* opposition to rebalancing of either costs, revenues or both.

Steven C Wieting

+1-212-816-7148

steven.wieting@citi.com

Shawn Snyder

shawn.snyder@citi.com

See Appendix A-1 for Analyst Certification, Important Disclosures and non-US research analyst disclosures.

Citi Research is a division of Citigroup Global Markets Inc. (the “Firm”), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Policy Cliffhanger to Come

- *"If there's a mandate in (November 6) results, it's a mandate for us to find a way to work together ...We're willing to accept new revenue under the right conditions. What matters is where the increased revenue comes from and what type of reform comes with it. Does the increased revenue come from government taking a larger share of what the American people earn through higher tax rates? Or does it come as a byproduct of growing our economy, energized by a simpler, cleaner, fairer tax code with fewer loopholes and lower rates for all?" Speaker of the House John Boehner, R-Oh, Nov. 7, 2012.*
- *"Raising tax rates is unacceptable. And, frankly, it couldn't even pass the House. I'm not sure it could pass the Senate," Boehner, Nov. 9, 2012.*
- *"We can't just cut our way to prosperity...That means we have to ask the wealthiest Americans to pay a little more in tax...I refuse to accept any approach that isn't balanced," President Barack Obama, Nov. 9, 2012.*
- *"There is no mandate for raising tax rates on the American people...There is a mandate for avoiding the fiscal cliff and finding real solutions so we can make life work for people again," House Majority Leader Eric Cantor, R-Va, Nov. 7, 2012.*
- *"The election was clear in several ways...The rich, the poor agree. The richest of the rich have to help a bit," Senate Majority Leader Harry Reid, D-NV, Nov. 7, 2012.*
- *"Some people out there think Tuesday's results mean Republicans in Washington are now going to roll over and agree to Democrat demands that we hike tax rates before the end of the year. I'm here to tell them there is no truth to that notion whatsoever," Senate Minority Leader Mitch McConnell, R-Ky, Nov. 9, 2012.*

The sizable stock market reaction to "status quo" U.S. election results last week – results entirely telegraphed by opinion polls and other barometers – may help underscore the magnitude of what's at stake: never in modern history has the near-term U.S. economic outlook depended so heavily on reaching a political agreement (see figures 1-2).

**The only post election certainty:
Democrats and Republicans are stuck
working together.**

Taken at face value, the comments of some policymakers quoted above almost suggest some deliberate *choice* that they are being asked to make that could derail the still weak U.S. economy. A *lack of action* is the threat, as policy tightening of historic scope *is already* current law for 2013. Ideally, such comments might simply reflect their expectation an eventual deal will be struck. It also likely reflects a reality that their immediate statements merely represent an opening gambit.


Interestingly, the comments from our market contacts in recent weeks have suggested complacency over the fiscal cliff issue that is apparently now unwinding. Some have asked for exacting details of the tax and spending path going forward as if the election had settled the matter. Instead, the only new certainty is that both Republicans and Democrats need to make policy together, or instead impose the "cliff" on the U.S. and world economy.

Figure 1. Major Elements of the Fiscal Tightening to Take Effect Jan. 1 2013 Under Current Law

	Calendar 2013	Percent of GDP
Bush era tax cuts, AMT patch	\$295	1.8%
Payroll tax holiday	127	0.8
Health Care Taxes	24	0.1
Other Expiring tax provisions	87	0.5
Budget Control Act (sequester)	87	0.5
Emergency Unemployment Benefits	35	0.2
Reduction in Medicare payment rates (Doc Fix)	15	0.1
Other changes in revenues and spending	140	0.9
Totals	\$808	5.0%

Sources: BEA, IRS, JCT, OMB, Treasury, and Citi Research.

Figure 2. Change in Total Personal Taxes as % of GDP (Estimate for 2013 Under Current Law Policy) and Real GDP, Y/Y%



Sources: BEA and Citi Research. Note: Includes 2012 estimate for GDP.


Gone for now are references to the tax and spending outlook as a mere “fiscal hill,” easily surmounted. Such might describe our own sitting assumption of incremental fiscal tightening in 2013 of little more than 1% of GDP. But this is an assumption that *requires* a deal, apparently one that will take great political agony to achieve. Only a shocking and unlikely turn away from *all* immediate fiscal restraint would leave the issue as benign as the “Y2K bug” as some suggested a few weeks back. This was before U.S. equities had dropped 5% amid a spike up in implied volatility in options markets.

While the weakening in risk assets is far from historic in magnitude, it is worrisome as it has always been clear that if a fiscal deal is to be reached within 2012, it would follow the usual pattern of stretched out and contentious negotiations. How much anxiety will be in place by late December if the issue is so distressing now? (To be clear, we don’t buy that Greece’s latest woes are the root of the post-election selloff.)

How much fiscal cliff anxiety will there be in December if the issue is already so distressing now?

We are also doubtful that anything but a resolution of cliff concerns will revive business investment, which seems poised to decline at least moderately through year end, barring assurances that demand isn’t derailed by the course of current law (see figure 3). How, for example will industries headed for revenue cuts under sequestration just assume “it won’t happen,” as President Obama noted in reference to the defense sector during last month’s debates?

Figure 3. Core Capital Goods Orders and Consumer Durables Spending (Billions of \$, SAAR)




Sources: BEA and Census.

Consider a standard unemployment rate still above the majority of post-war recessionary peaks.


Away from political considerations, *any* immediate fiscal tightening during a period when labor markets have suffered a lost decade or worse should be questioned.¹ Even an unemployment rate colored by poor labor force participation in recent years is *no lower* than the rate reached during the *peak* of most post war recessions, periods when policymakers generally sought fiscal easing (see figures 4-5).

Figure 4. Employed Share of U.S. Population (%) Age 16+



Source: BLS.

Figure 5. Unemployment Rate (%)



Source: BLS. Note: Shaded regions denote recession.

Some policymakers have hinted at a “grand bargain” as an alternative course for both parties. Striking such a comprehensive deal even in principal before the year

¹ Arguments against immediate rebalancing amid weak labor markets consider that prolonged periods of cyclical job market weakness cause a rise in structural unemployment with little lasting fiscal benefit. Please see our U.S. Macro Focus of August 28, 2012.

out may be wishful thinking, particularly when some consider the post election period as a chance to collect political spoils. But the Bowles-Simpson framework for tax reform (rejected so far) recognized the unique challenges the U.S. faces ahead, and in our view, represents the best path toward very gradually restoring fiscal balance without undermining near-term economic recovery.²


Doing so would remove major fiscal uncertainties short- and long-term, and leave the lean U.S. economy positioned for a stronger and more durable recovery than it has seen in the years following the financial crisis. The prospect of immediate new fiscal tightening in 2013 is the only significant restraint on our sitting forecast for growth limited near 2%, or far worse if policymakers leave the U.S. to “dig out” from under a cliff.

Like it or not, the Baby Boom cannot be ignored in assessing revenue needs or the programs to reform.

Bowles-Simpson included cuts in both marginal income tax rates and the vast tax expenditures (concentrated among upper income households) that hold down revenues.³ But it also recognized that the baby boom demographic cohort will claim an ever larger share of U.S. tax revenues for health care and retirement benefits, and simply won’t “go away” (see figures 6-8).


Government spending for healthcare, Social Security, defense and interest could represent 18% of U.S. GDP in just 10 years in some plausible projections. That’s the historical average *total* tax share of GDP that covered expenditures on *all* federal programs in the past four decades. Barring a severe scaling back of entitlement programs in the not distant future, tax revenues will have to adjust up somewhat relative to historic norms, or instead, U.S. debt will remain on an unsustainable upward trajectory.

Figure 6. Total Federal Revenues As % of GDP Under Bowles-Simpson Plan



Sources: OMB, Center on Budget and Policy Priorities, National Commission on Fiscal Responsibility and Reform, and Citi Research. Note: Forecast accounts for elements of the original Bowles-Simpson Plan already enacted.

Figure 7. Net Medicare Outlays as % of U.S. Wages and U.S. Population Share Medicare Eligible




Sources: Census, OMB, and Citi Research.

² Please see the U.S. Macro Focus of September 21, Nathan Sheets, Robert DiClemente et al.

³ Please see the U.S. Macro Focus of October 22 for discussion.

Figure 8. US Population Projections: 20-64 Years Old vs 65+ Y/Y%



Source: Census Bureau.

Some have clearly failed to recognize that the projected growth pace of entitlement expenditures, particularly healthcare spending, is unsustainable and unsupportable regardless of the level of upper income marginal tax rates. Others have looked to market cures for healthcare costs where no markets exist.⁴ In our view, hopes of abandoning the current, if inefficient system *entirely* appears so difficult and unlikely that such idealism risks ignoring a building fiscal crisis.

As figures 9-10 show, the U.S. has by far the world's highest per capita healthcare expenditures and by our studies, the highest *unit* healthcare costs per treatment as well. Within government programs with limited resources, it is surprising to see opposition to reasonable attempts to find less costly solutions to provide care. For those who don't want government interference, healthcare is available for purchase privately.


Blaming health insurance for U.S. healthcare costs is akin to blaming a credit card for a surprisingly large dinner bill.

Meanwhile, the bulk of the efforts to address U.S. healthcare have focused on insurance schemes alone, akin to blaming one's credit card for the size of a dinner bill. A long period of neglect in such issues and procrastination has left the fiscal outlook for the U.S. in dire need of reforms before very long.

The bulk of the fiscal cliff actually represents fiscal *indecision* in the past. Policymakers didn't want to recognize tax cuts of the past decade as permanent revenue losses, so now the "sun sets" before long. Other elements of the cliff, such as sequestration, reflect a failure to make careful and deliberate spending cuts in a super-committee process. It would be a shame if indecision now sinks the U.S. economy when the scars of the 2008-2009 down turn are so barely healed. Policymakers, for all their talk of cooperation, haven't decisively suggested they won't take the U.S. economy to the brink in their negotiations ahead.


⁴ Please see U.S. Macro Focus April 9, 2012, and "How Much Savings Is Left in U.S. Medicine? Lots," Peter Orszag, Bloomberg News, September 21, 2012.

Figure 9. Total Health Expenditure per Capita (PPP-Adjusted), U.S. and Selected Countries, 2009



Source: OECD. Note: All data are 2009 except the following: Italy, Canada, and Switzerland 2010; Australia and Japan 2008.

Figure 10. Life Expectancy of Total Population at Birth (Years), U.S. and Selected Countries, 2009



Source: OECD. Note: All data are 2009 except the following: Sweden and France 2010; Italy 2008, Canada 2007.

Appendix A-1

Analyst Certification

The research analyst(s) primarily responsible for the preparation and content of this research report are named in bold text in the author block at the front of the product except for those sections where an analyst's name appears in bold alongside content which is attributable to that analyst. Each of these analyst(s) certify, with respect to the section(s) of the report for which they are responsible, that the views expressed therein accurately reflect their personal views about each issuer and security referenced and were prepared in an independent manner, including with respect to Citigroup Global Markets Inc and its affiliates. No part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst in this report.

IMPORTANT DISCLOSURES

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability which includes investment banking revenues.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Research product ("the Product"), please contact Citi Research, 388 Greenwich Street, 28th Floor, New York, NY, 10013, Attention: Legal/Compliance [E6WYB6412478]. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

NON-US RESEARCH ANALYST DISCLOSURES

Non-US research analysts who have prepared this report (i.e., all research analysts listed below other than those identified as employed by Citigroup Global Markets Inc.) are not registered/qualified as research analysts with FINRA. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. The legal entities employing the authors of this report are listed below:

Citigroup Global Markets Inc

Steven C Wieting; Shawn Snyder

OTHER DISCLOSURES

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the issuer(s) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citi Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing public information on such security or any registered prospectus.

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

Important Disclosures for Morgan Stanley Smith Barney LLC Customers: Morgan Stanley & Co. LLC (Morgan Stanley) research reports may be available about the companies that are the subject of this Citi Research research report. Ask your Financial Advisor or use smithbarney.com to view any available Morgan Stanley research reports in addition to Citi Research research reports.

Important disclosure regarding the relationship between the companies that are the subject of this Citi Research research report and Morgan Stanley Smith Barney LLC and its affiliates are available at the Morgan Stanley Smith Barney disclosure website at www.morganstanleysmithbarney.com/researchdisclosures.

For Morgan Stanley and Citigroup Global Markets, Inc. specific disclosures, you may refer to www.morganstanley.com/researchdisclosures and https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures.

This Citi Research research report has been reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval was conducted by the same person who reviewed this research report on behalf of Citi Research. This could create a conflict of interest.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by.

The Product is made available in **Australia** through Citi Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992), participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in **Brazil** by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários, BACEN - Brazilian Central Bank, APIMEC - Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11º andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of **Canada** by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. This product is available in **Chile** through Banchile Corredores de Bolsa S.A., an indirect subsidiary of Citigroup Inc., which is regulated by the Superintendencia de Valores y Seguros. Agustinas 975, piso 2, Santiago, Chile. The Product is made available in **France** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 1-5 Rue Paul Cézanne, 8ème, Paris, France. The Product is distributed in **Germany** by Citigroup Global Markets Deutschland AG ("CGMD"), which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). CGMD, Reuterweg 16, 60323 Frankfurt am Main. Research which relates to "securities" (as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)) is issued in **Hong Kong** by, or on behalf of, Citigroup Global Markets Asia Limited which takes full responsibility for its content. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Research is made available through Citibank, N.A., Hong Kong Branch, for its clients in Citi Private Bank, it is made available by Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citibank N.A. is regulated by the Hong Kong Monetary Authority. Please contact your Private Banker in Citibank N.A., Hong Kong, Branch if you have any queries on or any matters arising from or in connection with this document. The Product is made available in **India** by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. The Product is made available in **Indonesia** through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kav. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. The Product is made available in **Israel** through Citibank NA, regulated by the Bank of Israel and the Israeli Securities Authority. Citibank, N.A. Platinum Building, 21 Ha'arba'ah St, Tel Aviv, Israel. The Product is made available in **Italy** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. Via dei Mercanti, 12, Milan, 20121, Italy. The Product is made available in **Japan** by Citigroup Global Markets Japan Inc. ("CGMJ"), which is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. If the Product was distributed by SMBC Nikko Securities Inc. it is being so distributed under license. In the event that an error is found in an CGMJ research report, a revised version will be posted on the Firm's Citi Velocity website. If you have questions regarding Citi Velocity, please call (81 3) 6270-3019 for help. The Product is made available in **Korea** by Citigroup Global Markets Korea Securities Ltd., which is regulated by the Financial Services Commission, the Financial Supervisory Service and the Korea Financial Investment Association (KOFIA). Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. KOFIA makes available registration information of research analysts on its website. Please visit the following website if you wish to find KOFIA registration information on research analysts of Citigroup Global Markets Korea Securities Ltd. <http://dis.kofia.or.kr/fs/dis2/fundMgr/DISFundMgrAnalystPop.jsp?companyCd=A03030&pageDiv=02>. The Product is made available in Korea by Citibank Korea Inc., which is regulated by the Financial Services Commission and the Financial Supervisory Service. Address is Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. The Product is made available in **Malaysia** by Citigroup Global Markets Malaysia Sdn Bhd (Company No. 460819-D) ("CGMM") to its clients and CGMM takes responsibility for its contents. CGMM is regulated by the Securities Commission of Malaysia. Please contact CGMM at Level 43 Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur, Malaysia in respect of any matters arising from, or in connection with, the Product. The Product is made available in **Mexico** by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, Integrante del Grupo Financiero Banamex ("Accival") which is a wholly owned subsidiary of Citigroup Inc. and is regulated by Comisión Nacional Bancaria y de Valores. Reforma 398, Col. Juárez, 06600 Mexico, D.F. In **New Zealand** the Product is made available to 'wholesale clients' only as defined by s5C(1) of the Financial Advisers Act 2008 ("FAA") through Citigroup Global Markets Australia Pty Ltd (ABN 64 003 114 832 and AFSL No. 240992), an overseas financial adviser as defined by the FAA, participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in **Pakistan** by Citibank N.A. Pakistan branch, which is regulated by the State Bank of Pakistan and Securities Exchange Commission, Pakistan. AWT Plaza, 1.1. Chundrigar Road, P.O. Box 4889, Karachi-74200. The Product is made available in the **Philippines** through Citicorp Financial Services and Insurance Brokerage Philippines, Inc., which is regulated by the Philippines Securities and Exchange Commission. 20th Floor Citibank Square Bldg. The Product is made available in the Philippines through Citibank NA Philippines branch, Citibank Tower, 8741 Paseo De Roxas, Makati City, Manila. Citibank NA Philippines NA is regulated by The Bangko Sentral ng Pilipinas. The Product is made available in **Poland** by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Nadzoru Finansowego. Dom Maklerski Banku Handlowego S.A. ul.Senatorska 16, 00-923 Warszawa. The Product is made available in the **Russian Federation** through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any

information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in **Singapore** through Citigroup Global Markets Singapore Pte. Ltd. ("CGMSPL"), a capital markets services license holder, and regulated by Monetary Authority of Singapore. Please contact CGMSPL at 8 Marina View, 21st Floor Asia Square Tower 1, Singapore 018960, in respect of any matters arising from, or in connection with, the analysis of this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore Branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Please contact your Private Banker in Citibank N.A., Singapore Branch if you have any queries on or any matters arising from or in connection with this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). This report is distributed in Singapore by Citibank Singapore Ltd ("CSL") to selected Citigold/Citigold Private Clients. CSL provides no independent research or analysis of the substance or in preparation of this report. Please contact your Citigold/Citigold Private Client Relationship Manager in CSL if you have any queries on or any matters arising from or in connection with this report. This report is intended for recipients who are accredited investors as defined under the Securities and Futures Act (Cap. 289). Citigroup Global Markets (Pty) Ltd. is incorporated in the **Republic of South Africa** (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in **Spain** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 29 Jose Ortega Y Gasset, 4th Floor, Madrid, 28006, Spain. The Product is made available in the **Republic of China** through Citigroup Global Markets Taiwan Securities Company Ltd. ("CGMTS"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan and/or through Citibank Securities (Taiwan) Company Limited ("CSTL"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan, subject to the respective license scope of each entity and the applicable laws and regulations in the Republic of China. CGMTS and CSTL are both regulated by the Securities and Futures Bureau of the Financial Supervisory Commission of Taiwan, the Republic of China. No portion of the Product may be reproduced or quoted in the Republic of China by the press or any third parties [without the written authorization of CGMTS and CSTL]. If the Product covers securities which are not allowed to be offered or traded in the Republic of China, neither the Product nor any information contained in the Product shall be considered as advertising the securities or making recommendation of the securities in the Republic of China. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security or financial products. Any decision to purchase securities or financial products mentioned in the Product must take into account existing public information on such security or the financial products or any registered prospectus. The Product is made available in **Thailand** through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in **Turkey** through Citibank AS which is regulated by Capital Markets Board. Tekfen Tower, Eski Buyukdere Caddesi # 209 Kat 2B, 23294 Levent, Istanbul, Turkey. In the **U.A.E.**, these materials (the "Materials") are communicated by Citigroup Global Markets Limited, DIFC branch ("CGML"), an entity registered in the Dubai International Financial Center ("DIFC") and licensed and regulated by the Dubai Financial Services Authority ("DFSA") to Professional Clients and Market Counterparties only and should not be relied upon or distributed to Retail Clients. A distribution of the different Citi Research ratings distribution, in percentage terms for Investments in each sector covered is made available on request. Financial products and/or services to which the Materials relate will only be made available to Professional Clients and Market Counterparties. The Product is made available in **United Kingdom** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in **United States** by Citigroup Global Markets Inc, which is a member of FINRA and registered with the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority.

Pursuant to Comissão de Valores Mobiliários Rule 483, Citi is required to disclose whether a Citi related company or business has a commercial relationship with the subject company. Considering that Citi operates multiple businesses in more than 100 countries around the world, it is likely that Citi has a commercial relationship with the subject company.

Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citi Research's Products can be found at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures.

Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations.

The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted.

Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product. With the exception of our product that is made available only to Qualified Institutional Buyers (QIBs) and other product that is made available through other distribution channels only to certain categories of clients to satisfy legal or regulatory requirements, Citi Research concurrently disseminates its research via proprietary and non-proprietary electronic distribution platforms. Periodically, individual Citi Research analysts may also opt to circulate research posted on such platforms to one or more clients by email. Such email distribution is discretionary and is done only after the research has been disseminated via the aforementioned distribution channels. Citi Research simultaneously distributes product that is limited to QIBs only through email distribution.

The level and types of services provided by Citi Research analysts to clients may vary depending on various factors such as the client's individual

preferences as to the frequency and manner of receiving communications from analysts, the client's risk profile and investment focus and perspective (e.g. market-wide, sector specific, long term, short-term etc.), the size and scope of the overall client relationship with Citi and legal and regulatory constraints. Citi Research product may source data from dataCentral. dataCentral is a Citi Research proprietary database, which includes Citi estimates, data from company reports and feeds from Reuters and Datastream.

© 2012 Citigroup Global Markets Inc. Citi Research is a division of Citigroup Global Markets Inc. Citi and Citi with Arc Design are trademarks and service marks of Citigroup Inc. and its affiliates and are used and registered throughout the world. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure of this report (the "Product"), including, but not limited to, redistribution of the Product by electronic mail, posting of the Product on a website or page, and/or providing to a third party a link to the Product, is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient to any third party. Where included in this report, MSCI sourced information is the exclusive property of Morgan Stanley Capital International Inc. (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, disseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are services marks of MSCI and its affiliates. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST
